Inteum Company
Links
seedsprint
Visible Legacy
RSS
News & Resources
Inteum Company News
Inteum Library
Subscribe
Autoantibodies for Identification of False Positives of Disease and Uses Thereof
Case ID:
M22-252LC^
Web Published:
3/29/2023
Autoantibodies are an excellent biomarker for both autoimmune disease and cancer, however, some autoantibodies, called common autoantibodies, have been found to occur frequently in healthy individuals. The presence of these common autoantibodies can impede the search for disease-linked autoantibodies or lead to false positives. The identification of common autoantibodies may simplify the discovery of autoantibodies specific to certain diseases.
Researchers at the Biodesign Institute of Arizona State University have developed a method for increasing the accuracy of a cancer or autoimmune screening by identifying at least one false positive indicator. By performing a meta-analysis of autoantibodyome data from 9 different case-control biomarker studies, they identified 77 common autoantibodies that are shared by healthy individuals. These common autoantibodies do not seem to lead to autoantibody-mediated pathology, and subcellular localization and tissue expression analysis show that this may be caused by inaccessibility to antibodies due to the autoantigen locations (e.g. intracellular sites, specific tissues/organs, etc.).
Because of the prevalence of these common autoantibodies, their identification may enhance autoimmune condition and cancer screening as well as facilitate a more holistic approach to understanding autoimmunity at the omics level.
Potential Applications
The use of autoantibodies to identify false positives in detecting cancer or autoimmune conditions
Autoimmunity research at the omics level
Help facilitate the elucidation of the complex immunology underlying their elicitation
Benefits and Advantages
May help identify false positives in cancer and autoimmunity screening
The most common autoantibodies occurred at similar frequencies in diseased cohorts to those in healthy cohorts
Indicates they were elicited through common non-pathogenic mechanisms
Comprehensive - meta-analysis of autoantibodyome data from 9 different case-control biomarker studies
Extensive quantification and statistical analyses were performed
For more information about this opportunity, please see
Shome et al - Cell Rep. - 2022
For more information about the inventor(s) and their research, please see
Dr. LaBaer's departmenal webpage
Dr. Chung's departmental webpage
Patent Information:
Title
App Type
Country
Serial No.
Patent No.
File Date
Issued Date
Expire Date
Direct Link:
https://canberra-ip.technologypublisher.com/tech?title=Autoantibodies_for_Ide ntification_of_False_Positives_of_Disease%0aand_Uses_Thereof
Keywords:
Bookmark this page
Download as PDF
For Information, Contact:
Jovan Heusser
Director of Licensing and Business Development
Skysong Innovations
jovan.heusser@skysonginnovations.com